tbuckley/cabot-search huggingface dataset:
Phenotyping the Responses to Systemic Corticosteroids in the Management of Asthma Attacks (PRISMA)
Authors: Carlos Celis-Preciado, Simon Leclerc, Martine Duval, Dominic O Cliche, Lucie Brazeau, Félix-Antoine Vézina, Marylène Dussault, Pierre Larivée, Samuel Lemaire-Paquette, Simon Lévesque, Philippe Lachapelle, Simon Couillard
Journal: European Respiratory Journal (2025)

Asthma attacks are heterogeneous. It is not known whether the response to oral corticosteroids (OCS) in acute asthma varies according to type-2 (T2) inflammatory biomarkers, blood eosinophil count (BEC) and exhaled nitric oxide (FeNO). We aim to explore the relationship between T2 biomarkers and response to OCS in acute asthma. We conducted a longitudinal observational study of people experiencing an asthma attack evaluated before and after a 7-day OCS course. The primary outcome was post-bronchodilator (BD) FEV1 change according to ordinal BEC-FeNO 3-group categories (T2-Low/Low, BEC <0.15×109 cells·L-1 and FeNO <25 ppb; T2-High/High, BEC ≥0.30×109 cells·L-1 and FeNO ≥35 ppb and T2-Mid, not meeting Low/Low-High/High criteria). A key secondary outcome was the Asthma Control Questionnaire (ACQ-5) change. Exploratory outcomes included OCS-attributable adverse events. Fifty-three people were enrolled with 16 (30%) T2-Low/Low, 27 (51%) T2-Mid and 10 (19%) T2-High/High asthma attacks. Post-BD FEV1 changes increased with combined BEC-FeNO elevation (p-for-interaction=0.007), peaking in the T2-High/High phenotype (0.390±0.512L, p-for-trend<0.0001). Conversely, T2-Low/Low attacked achieved nonsignificant FEV1 changes (0.017±0.153L). In univariable and multivariable analyses, only ordinal BEC-FeNO stratification - not symptoms nor FEV1 - was a predictor of subsequent post-BD FEV1 improvement. All patients improved ACQ-5, numerically peaking in the T2-High/High phenotype (-1.58±0.60, p-for-trend=0.08). All groups experienced similar OCS-attributable adverse events, with n=33 (62%) participants reporting ≥1 event. We found that objective improvement following OCS is confined to T2-High/High events. As in chronic asthma, greater T2 burden identifies a distinct clinical and therapeutic trajectory, whereas OCS-related adverse events are uniformly distributed.
Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in CCNE1-Aberrant Ovarian and Endometrial Tumors
Authors: Nealia C. House, Victoria E. Brown, Maxine Chen, Liang Yuan, Sydney L. Moore, Jian Guo, Yoon Jong Choi, Lakshmi Muthuswamy, Scott Ribich, Philip Ramsden, Kerrie L. Faia
Journal: Cancer Research (2025)

BLU-222 is an investigational, potent, highly selective, orally bioavailable CDK2 inhibitor in clinical development. BLU-222 demonstrated robust antitumor activity in select CCNE1-high ovarian and endometrial cancer models. We used a combination of CRISPR whole genome screens coupled with targeted genetic and pharmacologic approaches in ovarian and endometrial cell lines to identify biological determinants to predict BLU-222 monotherapy activity. Rb and p16 expression were biomarkers that enriched for CDK2-dependency/BLU-222 sensitivity in CCNE1 overexpressed, non-amplified cells. Further, intact Rb and low p16 expression predicted a BLU-222 and CDK4/6 inhibitor combination response. BLU-222 demonstrated robust activity in combination with carboplatin or paclitaxel in CCNE1-aberrant models, rendering chemotherapy-resistant tumors strongly sensitive to the combination. These findings demonstrate that response to CDK2 inhibition by BLU-222 can be further predicted using a combinatorial biomarker signature that could refine patient selection criteria in CCNE1-high patients and support clinical development.
Tumor Suppressors Condition Differential Responses to the Selective CDK2 Inhibitor BLU-222
Authors: Adam P. Dommer, Vishnu Kumarasamy, Jianxin Wang, Thomas N. O'Connor, Michelle Roti, Sidney Mahan, Karen McLean, Erik S. Knudsen, Agnieszka K. Witkiewicz
Journal: Cancer Research (2025)

Abstract CDK2 inhibitors have recently been developed and entered clinical trials. Combination approaches can help broaden the use of therapeutic agents and establish more effective treatments. Here, we evaluated the selective CDK2 inhibitor BLU-222 for mechanisms of response in the context of ovarian and breast cancer models. Sensors of cellular CDK activity indicated that sensitivity to either CDK4/6 or CDK2 inhibition was related to the differential dependence on a single CDK for G1/S transition. Unlike CDK4/6 inhibitors, BLU-222 was able to robustly inhibit proliferation through cell cycle inhibition in both G1 and G2 phases. However, it remained possible for cells to re-enter the cell cycle upon drug withdrawal. The anti-proliferative strength and impact on G1/S versus G2/M accumulation was mediated by the RB tumor suppressor. To broaden the sensitivity to CDK2 inhibition, combinatorial drug screens were performed that identified both synergistic (e.g., CDK4/6 inhibitors) and antagonistic (e.g., WEE1 inhibitors) relationships. Models that were exceptionally sensitive to CDK2 inhibition displayed coordinate expression of cyclin E1 and P16INK4A, an endogenous CDK4/6 inhibitor. Functional studies demonstrated that P16INK4A and CDK4/6 activity were key mediators of sensitivity to BLU-222. Clinical gene and protein expression analysis revealed a positive correlation between cyclin E1 and P16INK4A and identified that ~25% of ovarian cancers exhibited coordinate expression of cyclin E, P16INK4A, and RB, indicative of strong sensitivity to CDK2 inhibition. Together, this work advances a precision strategy for the use of CDK2 inhibitors in the context of ovarian and breast cancers.
Publisher Correction: The ENCODE Imputation Challenge: a critical assessment of methods for cross-cell type imputation of epigenomic profiles
Authors: Jacob Matthew Schreiber, Carles A. Boix, Jin wook Lee, Hongyang Li, Yuanfang Guan, Chun-Chieh Chang, Jen-Chien Chang, Alex Hawkins-Hooker, Bernhard Schölkopf, Gabriele Schweikert, Mateo Rojas Carulla, Arif Canakoglu, Francesco Guzzo, Luca Nanni, Marco Masseroli, Mark James Carman, Pietro Pinoli, Chenyang Hong, Kevin Y. Yip, Jefrey P. Spence, Sanjit Singh Batra, Yun S. Song, Shaun Mahony, Zheng Zhang, Wuwei Tan, Yang Shen, Yuanfei Sun, Minyi Shi, Jessika Adrian, Richard S. Sandstrom, Nina P. Farrell, Jessica M. Halow, Kristen Lee, Lixia Jiang, Xinqiong Yang, Charles B. Epstein, J. Seth Strattan, Bradley E. Bernstein, Michael P. Snyder, Manolis Kellis, William S. Noble, Anshul Bharat Kundaje
Journal: Genome biology (2025)
<i>Notes from the Field</i>: Seroprevalence of Highly Pathogenic Avian Influenza A(H5) Virus Infections Among Bovine Veterinary Practitioners — United States, September 2024
Authors: Jerome Leonard, Elizabeth J. Harker, Christine M. Szablewski, Sara F. Margrey, K. Fred Gingrich, Keyana Crossley, Emily Fletcher, Claire J. McCreavy, Sabrina Weis-Torres, Dennis Wang, Emma K. Noble, Min Z. Levine, H. Pamela Pagano, Crystal Holiday, Feng Liu, Stacie Jefferson, Zhu-Nan Li, F. Liaini Gross, Carrie Reed, Sascha Ellington, Alexandra M. Mellis, Samantha M. Olson
Journal: MMWR Morbidity and Mortality Weekly Report (2025)
Effective Treatment of Disseminated Prostate Cancer Using CD46-Targeted 225Ac Therapy
Authors: Anil P. Bidkar, Robin Peter, Anju Wadhwa, Kondapa Naidu. Bobba, Scott Bidlingmaier, Niranjan Meher, Jonathan Chou, Nancy Greenland, Chandrashekhar Dasari, Shubhankar Naik, Athira Raveendran, Megha Basak, Juan Antonio Camara Serrano, Veronica Steri, Scott Kogan, Adam Oskowitz, Jiang He, David M. Wilson, Rahul Aggarwal, Renuka Sriram, Henry F. VanBrocklin, Youngho Seo, Bin Liu, Robert R. Flavell
Journal: Clinical Cancer Research (2025)

Abstract Purpose: Metastatic castration-resistant prostate cancer (mCRPC) has limited treatment options and a poor prognosis. Recently, PSMA-targeted alpha particle therapy agents using Actinium-225 (225Ac) have shown promising results for prostate cancer treatment, but a significant fraction of patients with advanced mCRPC demonstrate loss of PSMA expression. We have previously reported that PSMA-null and PSMA-positive tumors can be detected and treated effectively with CD46-targeted radiopharmaceuticals. This study evaluates the CD46-targeting PET imaging agent [89Zr]DFO-YS5 and the radioimmunotherapy agent [225Ac]Macropa-PEG4-YS5 in disseminated prostate cancer tumors. Experimental Design: Microtumor lesions, primarily observed in the liver, kidneys, and lungs, were successfully detected with [89Zr]DFO-YS5 PET imaging. We used disseminated 22Rv1 tumors for biodistribution studies, dosimetry assessments, and therapeutic efficacy evaluations of [225Ac]Macropa-PEG4-YS5. Results: Quantitative digital alpha-particle autoradiography revealed high radiation dose deposition from [225Ac]Macropa-PEG4-YS5 in microtumors compared to surrounding liver tissues, although in larger lesions (&amp;gt;1 mm diameter) the dose distribution was heterogeneous. Early treatment of smaller disseminated tumors with uniform radiation dose was more effective in ablating tumors and promoting survival. In late-stage lesions of large size, heterogeneous dose deposition limited therapeutic efficacy, requiring higher administered activity to achieve a complete response. Conclusions: Our findings highlight that [225Ac]Macropa-PEG4-YS5 holds the potential for clinical translation for metastatic prostate cancer and reinforces the value of microdosimetry in understanding the efficacy of and resistance to targeted alpha therapy.
First Clade Ib Monkeypox Virus Infection Reported in the Americas — California, November 2024
Authors: Vivian Levy, Anna Branzuela, Kristina Hsieh, Shiffen Getabecha, Ricardo Berumen, Kayla Saadeh, Robert E. Snyder, Gillian Marek, Daniel Dodson, Alyssa Newman, Jill K. Hacker, Chantha Kath, Faisal S. Minhaj, Crystal M. Gigante, Shannon Gearhart, Alexander Kallen, Christina L. Hutson, Kathleen Jacobson, Robert Avina, Josh Bunao, Jahara Cayabyab, Edwin Chojolan, Erin Epson, Alex Espinosa, Bianca Gonzaga, Monica Haw, Kelly A. Johnson, Awa Keinde, Deidra Lemoine, Kelsey Maccuish, Alexia McGonagle, Rilene Ng, Rachel Piper, Will Probert, Maria Salas, Brandon Stavig, Juliet Stoltey, Orlanda Tafolla, Eric C. Tang, Debra A. Wadford, Jessica Watson, Vivian Wong, Ermias Belay, Shama Cash-Goldwasser, Whitni Davidson, Jiusheng Deng, Marie De Perio, Alida Gertz, David W. Hunter, Aaron Kofman, Ryan Lash, Andrea M. McCollum, A.D. McNaghten, Agam K. Rao, Panayampalli S. Satheshkumar, Emily Sims, Ian Williams, Italo Zecca
Journal: MMWR Morbidity and Mortality Weekly Report (2025)

A clade I monkeypox virus (MPXV) outbreak is ongoing in the Democratic Republic of the Congo; travel-associated clade I MPXV infections have been reported in non-African countries. In November 2024, San Mateo County Health in California identified an electronic laboratory report of polymerase chain reaction results suggestive of clade I MPXV infection in a male traveler who had recently returned from East Africa. After conferring with the California Department of Public Health (CDPH), a county health department worker visited the patient that same day at his home and obtained skin pustule swab specimens for expedited clade I MPXV testing. Clade I MPXV was confirmed the following day by the CDPH Viral and Rickettsial Disease Laboratory. This was the first reported clade I MPXV infection in the Americas. Among 83 identified contacts, five received JYNNEOS vaccine as postexposure prophylaxis. All contacts were monitored for 21 days; no secondary cases were identified. Patients with mpox-compatible lesions or clinical features should receive MPXV testing, and health care providers should immediately notify public health authorities of suspected clade I MPXV infections (e.g., mpox manifestations and travel history to an area with ongoing clade I MPXV transmission) or upon receiving a nonvariola orthopoxvirus DNA detected, clade II MPXV DNA undetectable test result to trigger additional testing and facilitate the rapid implementation of transmission-based precautions and other preventive public health interventions.
Restoration of the Tumor Suppressor Function of Y220C-Mutant p53 by Rezatapopt, a Small Molecule Reactivator
Authors: Anna M. Puzio-Kuter, Lizhong Xu, Mary Kate McBrayer, Romyr Dominique, Hongju H. Li, Bruce J. Fahr, Alyssa M. Brown, Amy E. Wiebesiek, Brandon M. Russo, Chris L. Mulligan, Hong Yang, Josh Battaglia, Kimberly A. Robell, Dafydd H. Thomas, Kuo-Sen Huang, Alexander Solovyov, Benjamin D. Greenbaum, Jonathan D. Oliner, Thomas W. Davis, Melissa L. Dumble, Melissa L. Johnson, Shunbin Xiong, Peirong Yang, Guillermina Lozano, Marc M. Fellous, Binh T. Vu, Alison M. Schram, Arnold J. Levine, Masha V. Poyurovsky
Journal: Cancer Discovery (2025)

Abstract Restoration of the tumor suppressor function of tumor-associated p53 mutants, including the Y220C substitution, has posed a significant challenge for therapeutic discovery. Here, we describe rezatapopt (PC14586), part of a series of compounds designed to reactivate the p53 Y220C mutant. These compounds restore p53 tumor suppressor function by correcting its conformation and enabling it to bind DNA and activate downstream target genes, thus inducing anti-proliferative changes in tumor cells. Our findings are supported by biochemical and structural analysis, in vitro and in vivo transcriptomics, and functional data, revealing the recovery of multiple aspects of the wild type p53 program. These compounds demonstrate potent anti-tumor activity in preclinical models as single agents and in combination with immunotherapy. Currently, rezatapopt is being evaluated in a registrational Phase 2 clinical trial for patients with advanced solid tumors harboring the TP53 Y220C mutation.
Preventing oxygen desaturation during bronchoscopy in COPD patients using high flow oxygen<i>versus</i>standard management: the randomised controlled PROSA 2 Trial
Authors: Andrei M Darie, Leticia Grize, Kathleen Jahn, Anna Salina, Jonathan Röcken, Matthias J Herrmann, Maria Pascarella, Vivian Suarez, Werner Strobel, Michael Tamm, Daiana Stolz
Journal: European Respiratory Journal (2025)

Background Patients with chronic obstructive pulmonary disease (COPD) are at increased risk for developing additional respiratory comorbidities associated with smoking, and are thus prone to undergo flexible bronchoscopy. However, COPD patients have increased periprocedural complications risk and lower oxygen saturation during bronchoscopy. Methods This was an investigator-initiated, single centre, open-label randomised controlled trial designed to assess the benefits of high flow nasal oxygen compared to conventional low flow oxygen by nasal cannula during conscious sedation for bronchoscopy in patients with COPD. Low flow was supplied at a starting rate of 4 L / min and gradually increased up to 12 L / min to maintain the oxygen saturation (SpO2) above 90%. High flow delivered using LM Flow 100 (Löwenstein Medical GmbH, Bad Ems, Germany) starting at a rate of 60 L / min and an inspired fraction of oxygen (FiO2) of 0.6 was increased up to 80 L / min to preserve the SpO2 above 90%. The primary endpoint was cumulative hypoxaemia time. Results We randomised 600 COPD cases with a median age of 69.0 (62.0–76.0) years to either high flow (295) or low flow (305). The cumulative hypoxaemia time was 53% lower in the high flow group (1.8% [95%CI 1.5–2.2] versus 3.8% [95%CI 3.2–4.5] of monitoring time, p&lt;0.001). Additionally, the high flow group experienced 3.0 (1.0–6.0) hypoxaemia events (SpO2&lt;90%) as compared to 6.0 (3.0–10.0) in the low flow group (p&lt;0.001). The low flow group had five-fold higher odds of experiencing hypoxaemia during bronchoscopy (OR 5.1 [95%CI 3.2–8.2], p&lt;0.001). Conclusion High flow is feasible, decreases cumulative hypoxaemia time and reduces hypoxaemia events during bronchoscopy in patients with COPD but does not impact patient comfort. Clinical trial registration This trial was registered on the International Clinical Trials Registry Platform, ISRCTN18159882 .
Association of fibrotic-related extracellular vesicle microRNAs with lung involvement in systemic sclerosis
Authors: Julien Guiot, Béatrice André, Judith Potjewijd, Pierre Jacquerie, Sébastien Cremers, Monique Henket, Latifa Idoufkir, Claire Remacle, Rachid Tobal, Laurie Giltay, Catherine Moermans, Fanny Gester, Barbara Polese, Malik Hamaïdia, Ingrid Struman, Edouard Louis, Michel Malaise, Dominique de Seny, Pieter van Paassen, Renaud Louis, Clio Ribbens, Makon-Sébastien Njock
Journal: European Respiratory Journal (2025)

Background There is a pressing need to identify early biomarkers of lung involvement in systemic sclerosis (SSc) to start as soon as possible antifibrotic therapy. We aimed to identify extracellular vesicle-derived microRNAs (EV-miRNAs) that are differentially expressed between SSc patients with and without interstitial lung disease (ILD), explore their diagnostic value and investigate their functional properties. Methods Small EVs (sEVs) derived from plasma were isolated from 91 well-characterised SSc patients with ILD (SSc-ILD, n=45), without ILD (SSc-no ILD, n=46) and 43 matched healthy subjects (HS). Small RNA sequencing followed by quantitative RT-PCR were used to identify and validate sEV-miRNAs associated to SSc-ILD. Correlations between SSc-ILD-associated miRNAs and clinical parameters were assessed, as well as the impact of related miRNAs/sEVs on fibrosis. Results We identified a 4-miRNA signature associated with ILD in SSc context (miR-584-5p, miR-744-5p, miR-1307-3p and miR-10b-5p) (ROC AUC=0.85, 95% CI 0.76–0.94, p&lt;0.0001). Deeper analysis revealed a correlation of these candidates with pulmonary function tests (DLCO and FVC), highlighting their capacity to monitor lung fibrosis progression in SSc patients. Furthermore, SSc-ILD-associated sEV miRNAs are positively correlated and enriched in circulating lymphocytes, suggesting that these immune cells are their cellular source. Finally, functional studies highlighted an alteration of functional properties of sEVs in SSc-ILD context mainly due to the transfer of profibrotic miR-584–5p in lung fibroblasts. Conclusions Our sEV-based biomarker approach enabled to identify a promising 4-miRNA signature characteristic of ILD in SSc patients. Furthermore, the profibrotic properties of SSc-ILD-associated sEVs suggest a prominent role of these vesicles on SSc severity.
Self-Regulating Immunosuppressive Tumor Microenvironment by NIR-II Photothermal Agent with Anti-Inflammatory Activity for Self-Reinforcing Immunotherapy Synergy with Cancer Photothermal Ablation
Authors: Min Liu, Yiwen Tang, Mijia Yan, Jiale Zhang, Hangrong Chen, Qiuhong Zhang
Journal: Biomaterials (2025)
Lnc-H19-derived protein shapes the immunosuppressive microenvironment of glioblastoma
Authors: Junju Chen, Yixin Gao, Jian Zhong, Xujia Wu, Zhaojie Leng, Ming Liu, Yesheng Wang, Yuan Wang, Xuesong Yang, Nunu Huang, Feizhe Xiao, Maolei Zhang, Xuesong Liu, Nu Zhang
Journal: Cell Reports Medicine (2025)
Immuno-epidemiologic mapping of HLA diversity across glioma patient cohorts
Authors: Zujian Xiong, Kyle M Walsh, Chaim T Sneiderman, Michal Nisnboym, Costas G Hadjipanayis, Sameer Agnihotri, Todd N Eagar, Hong Wang, Ian F Pollack, Thomas G Forsthuber, Xuejun Li, Itay Raphael, Gary Kohanbash
Journal: Neuro-Oncology (2025)

Abstract Background Individual-level characteristics underlying population-level variation in glioma risk and outcomes remain incompletely understood. Cancer immunosurveillance, host immunity, and some immunotherapies center on the ability of an individual’s immune cells to recognize antigen epitopes presented on MHC molecules. Inter-individual variation in HLA alleles can elicit distinct repertoires of tumor antigen for presentation to immune cells. Therefore, HLA alleles may impact glioma incidence and prognosis. Methods HLA class I (HLA-I) alleles were identified using sequencing data from four large glioma cohorts and healthy cohorts, matched on ancestry, and race- and age-matched imputed cohorts developed by the Hardy-Weinberg equilibrium were referred to determine odds ratio incidence estimated by logistic regression. HLA prognostication was quantified by Cox regression. Results We analyzed 1,215 cases of glioma patients from non-Hispanic Whites and Asians. The HLA-I allelic frequencies of gliomas generally corresponded to their distribution within each race. However, specific HLA-I alleles were significantly associated with glioma incidence and prognosis, which differ between races but were independent of age and sex. Notably, non-Hispanic White glioma patients exhibited greater HLA homozygosity rates compared with race-matched controls. HLA-C01:02 and HLA-C07:02 displayed opposing effects on glioma prognosis between races. The distinct effects were associated with their capability of presenting specific mutations that appeared at the initial or late phase of glioma progression. Conclusions Expression of specific HLA-I alleles are associated with glioma incidence and prognosis within race. HLA-I-homozygosity is a risk factor for glioma in non-Hispanic Whites. These findings may guide development of precision-guided immunotherapies for glioma.
IgG-seq identifies immune-reactive enteric bacteria in Crohn’s disease with spondyloarthritis
Authors: Grace A. Maldarelli, Maeva Metz, Seun Oguntunmibi, Nancy Tran, Grace Xiang, Dana Lukin, Ellen J. Scherl, Randy S. Longman
Journal: Gut Microbes (2025)

Joint inflammation is the most common extraintestinal manifestation of Crohn's disease (CD). Although alterations in the enteric microbiota are described in CD with spondyloarthritis (CD-SpA), it is not known whether distinct taxa serve as markers for clinical subtypes of axial (AxSpA) or peripheral SpA (pSpA) in CD. Moreover, it is not yet known whether these taxa generate a specific systemic IgG response. Here, we sequenced the fecal microbiome from 106 individuals (44 CD, 39 CD-SpA, 14 CD-AxSpA, and 9 healthy controls [HC]). This unique cohort revealed distinct taxonomic compositions of CD and CD-SpA compared to HC and demonstrates that the composition of the CD-AxSpA microbiome is distinct from that of CD-pSpA. Using autologous serum, we identified enteric bacteria recognized by serum IgG and demonstrate differences in the IgG coating index of specific bacterial genera associated with CD-SpA. The IgG coating index of Mediterraneibacter gnavus differentiated patients with CD-pSpA and is positively associated with joint disease activity. This work illustrates divergent microbiome compositions in CD-SpA subtypes, as well as the recognition of distinct enteric bacteria by serum IgG with the potential to serve as a marker of joint inflammation in CD.
SHCBP1 is a novel regulator of PLK1 phosphorylation and promotes prostate cancer bone metastasis
Authors: Chen Tang, Shengmeng Peng, Yongming Chen, Bisheng Cheng, Shurui Li, Jie Zhou, Yongxin Wu, Lingfeng Li, Haitao Zhong, Zhenghui Guo, Yiming Lai, Hai Huang
Journal: MedComm (2025)

Prostate cancer is a common male genitourinary malignancy with bone metastasis posing challenges for prognosis and treatment. This study aimed to investigate the role of SHC protein SH2 structural domain binding protein 1 (SHCBP1) in prostate cancer bone metastasis. Whole transcriptome sequencing of prostate cancer samples was conducted to identify oncogene expression, specifically focusing on SHCBP1. In vivo and in vitro models were used to study SHCBP1's impact on bone metastasis. Through co-immunoprecipitation, mass spectrometry, and Western blot assays, the interaction between SHCBP1 and cell cycle-related proteins was elucidated, along with analysis of downstream protein partners. SHCBP1 was found to enhance prostate cancer cell development, metastasis, and mitosis, with the SHCBP1-polo-like kinase 1 (PLK1)-CDC25C axis playing a key role in promoting tumorigenesis. Therapeutic inhibition of SHCBP1 increased docetaxel sensitivity. Clinical data showed elevated SHCBP1 expression in advanced prostate cancer stages. These findings offer insights into potential therapeutic strategies for prostate cancer bone metastasis and highlight the significance of the SHCBP1-PLK1-CDC25C axis in docetaxel sensitivity.